Neurocrine Biosciences | NBIX - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 5.23B 400M 2025-12
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Cytokinetics USD 122.52M 102.95M 2025-12
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Exelixis USD 482.49M 106.19M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Pfizer USD 1.34B 295M 2025-09
Prothena USD 307.53M 23.31M 2025-12
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Repligen USD 566.02M 182.73M 2025-12
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12
Xoma USD 143.9M 7.68M 2024-06